Canary Islands, first European destination in ROBLOX
17.1.2025 13:00:00 CET | news aktuell GmbH | Press Release
Turismo de Canarias presents Find the Seasouls, an interactive experience within ROBLOX designed to promote environmental care in new generations, calling for respect for natural parks, protected spaces and the biodiversity of the islands
Madrid - Canary Islands Tourism is moving into the future with the launch of Find the Seasouls, Europe's first destination experience within ROBLOX, the immersive global social platform that has more than 80 million daily active users around the world and that It is currently one of the main meeting places for the Alpha and Z generations.
Find the seasouls is an interactive experience designed to encourage care for the environment in new generations, calling for respect for natural parks, protected spaces and the biodiversity of the islands. Users travel with their avatar through the 8 Canary Islands, visiting landscapes such as the volcanoes of Lanzarote or the junipers of El Hierro, and they look for very special sea creatures, the Seasouls, characters inspired by animals that inhabit the islands. These creatures and their description have been created in collaboration with the prestigious oceanographer Cristina Fernández Gil, seeking to be faithful to the biodiversity of the Islands.
The traveler of the future learns by playing
The objective of this project is to connect with the tourist of the future (Alpha and Z generations), influencing the education of caring for the environment when visiting destinations .
Since the experience is mainly aimed at the little ones, it has been designed prioritizing values linked to sustainability and taking into account a maximum exposure time to the screen. Roblox automatically translates the video game into fourteen languages, including Spanish, English, German, French, and Portuguese.
Find the Seasouls is a project by the creative agency Flecher.co developed by Brandnewverse, subsidized by the European Regional Development Fund (ERDF).
Contacts
Jone Urrutia
jone@flecher.co
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
FEV collaborates with Microsoft on efficient AI model approach for in‑car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press Release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities . The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio och Acrobat AI Assistant: nya generationens AI-drivna produktivitet – nu på svenska8.7.2026 15:02:57 CEST | Press Release
SAN JOSE, Kalifornien – 08 juli 2026 – Adobe utökar tillgängligheten till Acrobat Studio och Acrobat AI Assistant i Sverige. De AI-drivna funktionerna för produktivitet och kreativitet erbjuds nu även på svenska, så att användarna kan använda dem på sitt lokala språk. Acrobat Studio kombinerar Adobe Acrobat Pro, Adobe Express Premium och intelligenta AI-assistenter. Acrobat AI Wizard erbjuds dessutom som ett separat tillägg för alla Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard och Acrobat Pro) – ett flexibelt alternativ för alla som vill använda AI-drivna funktioner endast när de arbetar med dokument. Båda dessa erbjudanden gör det möjligt för användare att snabbare komma åt information i PDF-filer och Office-dokument, skapa innehåll och effektivisera arbetsflöden. Acrobat Studio och Acrobat AI Assistant är en viktig milstolpe i vidareutvecklingen av PDF, som har etablerat sig över hela världen som standardformatet för viktiga dokument sedan Adobes lansering år 1993. Acrob
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:22:07 CEST | Press Release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist and Modulator (SEGRAM), is an orally available investigational compound being developed to provide an alternative to glucocorticoid-based treatments such as prednisone, the current standard of care in DMD. Conventional glucocorticoids bind to the glucocorticoid receptor and influence gene expression. Among other mechanisms, this triggers two patterns of activity: transrepression, mainly linked to anti-inflammatory effects, and transactivation, predominantly associated with metabolic and growth-related side effects. In contrast, SEGRAMs are designed to influence receptor activity in a way that emphasises anti-inflammatory pathways. While this has not yet be
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 11:58:39 CEST | Press Release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
YouGov survey in 14 countries: Trust in router manufacturers from different regions European consumers mistrust Chinese routers29.6.2026 10:00:00 CEST | Press Release
European routers enjoy a high level of trust across Europe (60%) For half of Europeans (55%), the ‘Made in Europe’ label important to when making a purchase More than half of consumers in Sweden mistrust routers from Chinese manufacturers (60%) Many mistrust devices made in the USA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom